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Introduction: Under normal conditions, the spatial distribution of resting cerebral blood ﬂow and cerebral meta-
bolic rate of glucose are closely related. A relatively newmagnetic resonance (MR) technique, pseudo-continuous
arterial spin labeling (PCASL), can be used to measure regional brain perfusion. We identiﬁed a Parkinson's
disease (PD)-related perfusion and metabolic covariance pattern in the same patients using PCASL and FDG-
PET imaging and assessed (dis)similarities in the disease-related pattern between perfusion and metabolism in
PD patients.
Methods: Nineteen PD patients and seventeen healthy controls underwent [18F]-ﬂuorodeoxyglucose positron
emission tomography (FDG-PET) imaging. Of 14 PD patients and all healthy controls PCASL-MRI could be obtain-
ed. Data were analyzed using scaled subproﬁle model/principal component analysis (SSM/PCA).
Results: Unique Parkinson's disease-related perfusion and metabolic covariance patterns were identiﬁed using
PCASL and FDG-PET in the same patients. The PD-related metabolic covariance brain pattern is in high accor-
dance with previously reports. Also our disease-related perfusion pattern is comparable to the earlier described
perfusion pattern. The most marked difference between our perfusion and metabolic patterns is the larger per-
fusion decrease in cortical regions including the insula.
Conclusion: We identiﬁed PD-related perfusion and metabolic brain patterns using PCASL and FDG-PET in the
same patients which were comparable with results of existing research. In this respect, PCASL appears to be a
promising addition in the early diagnosis of individual parkinsonian patients.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
For many years, nuclear imaging techniques have been used to visu-
alize disease-related changes in brain perfusion and glucosemetabolism
in neurodegenerative brain diseases.
Sokoloff et al. were the ﬁrst to report that under physiological steady
state conditions, cerebral blood ﬂow (CBF) is coupled to the level of cere-
bral oxygen (CMRO2) and glucose consumption (Sokoloff, 1977).
Leenders et al. measured rCBF and rCMRO2 in patients with Parkinson's
disease (PD). They showed an increase of regional blood ﬂow and oxy-
genmetabolism in the basal ganglia of the affected hemisphere in PD pa-
tients with predominantly unilateral disease (Leenders, and Wolfson,
1984). In the 1980s, a SPECT tracer, 99Tcm-hexamethylpropyleneaminegy, University Medical Center
0 RB, The Netherlands.
. This is an open access article underoxime (99Tcm-HM-PAO), was developed to detect cerebral blood ﬂow
with SPECT-imaging. The PET tracer [18F]-ﬂuorodeoxyglucose (FDG) al-
lows the measurement of cerebral metabolic rate of glucose (CMRglc).
Regional differences in cerebral glucose metabolism have been reported
in parkinsonian syndromes using univariate methods (Teune et al.,
2010). Data-drivenmultivariatemethods are increasingly used to exam-
ine disease-speciﬁc metabolic covariance patterns in parkinsonian syn-
dromes (Ma et al., 2007; Teune et al., 2013). This has improved our
understanding of the pathophysiology of these diseases as well as our
ability to diagnose patients at an earlier disease stage (Tang et al., 2010a).
Ma et al. reproduced this PD-related metabolic covariance pattern,
using H215O PET scanning, indeed suggesting that cerebral blood ﬂow
and glucose metabolism are tightly coupled in PD patients (Ma et al.,
2007). However, in clinical practice, blood ﬂow measurements with
PET are not widely used because it is a demanding and time-
consuming procedure, while spatial resolution of SPECT is less optimal.
Recently, it has become possible to measure brain perfusion with athe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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(PCASL). It permits the noninvasive measurement of perfusion with
MRI by using a train of radio frequency (RF) pulses and magnetic ﬁeld
gradient pulses to achieve labeling of spins in ﬂowing blood (Dai et al.,
2008; van Osch et al., 2009). Ma et al. analyzed the expression of the
existing PD-related metabolic covariance pattern in a small number of
parkinsonian patients using perfusion MRI (continuous arterial spin la-
beling) and concluded that perfusion MRI can be used for accurate
quantiﬁcation of disease-related covariance patterns (Ma et al., 2010).
Melzer et al. were the ﬁrst to identify a PD-related perfusion covariance
pattern (Melzer et al., 2011).
In this study we identiﬁed a PD-related perfusion and metabolic co-
variance pattern in the samepatients using PCASL and FDG-PET imaging
and assessed (dis)similarities in the disease-related pattern between
perfusion and metabolism in PD patients.
2. Patients & methods
2.1. Subjects
The studywas approved by themedical ethics committee of theUni-
versity Medical Center Groningen. Voluntary written informed consent
was obtained from each subject after verbal and written explanation of
the study, in accordance with the Declaration of Helsinki. This study
aimed to include 17 healthy controls and 20 PD patients in which
FDG-PET and different MR image modalities were to be recorded. All
healthy controls underwent both FDG-PET and PCASL-MRI. One PD pa-
tient did not have an FDG-PET scan. Three PD patients appeared not to
be MRI proof (due to dental implants, large artifacts on functional
MRI) and in 2 PD patients PCASLwas not correctly recorded due to tech-
nical issues. In the current analysis we have 17 gender and age-matched
healthy controls (HC) (5 females, 12 males; mean age 61.5 years) and
19 PD patients (6 females, 13 males; mean age 63.9 years) but only 14
PD patients (4 females, 10males; mean age 63.8 years) who underwent
both FDG-PET and PCASL. PD patients had to fulﬁll the UK Brain Bank
criteria for PD (Litvan et al., 2003). Healthy controls were not allowed
to have ﬁrst-degree family members with parkinsonism or dementia.
All subjects underwent MRI and within 8 weeks an FDG-PET scan and
two neuropsychological tests (Mini Mental State Examination (MMSE)
and Frontal Assessment Battery (FAB)) and PD patients underwent ex-
amination using the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS)
part 3: motor symptoms. Neuropsychological scores did not differ sig-
niﬁcantly between groups (mean HC: MMSE 29, FAB 17; mean PD
(19): MMSE 29, FAB 16, mean PD (14): MMSE 28, FAB 16) indicating
that PD patients were non-demented. PD patients hadmild tomoderate
motor symptoms with Hoehn & Yahr stage: mean (in both 19 and 14
groups) 1 and standard deviation (SD) 1 vs 0.5 and a UPDRS part 3: in
both 19 and 14 groups mean 18; SD 7. Antiparkinsonian medication
was withheld for at least 12 hours and benzodiazepines were withheld
24 hours before MRI and FDG-PET scanning.
2.2. Image acquisition and preprocessing
MR imaging was performed on a 3 T MRI scanner (Achieva 3 Tesla,
Philips Healthcare, Best, The Netherlands) using a standard 8-channel
SENSE head coil. Subjects were wearing ear protection and instructed
to lie still with their eyes closed, and to avoid falling asleep.
To enable PCASL imaging, the scanner was equippedwith locally de-
veloped software. Pseudo-continuous labeling was performed by
employing a train of Hanning-shaped RF pulses (tip angle 18°, duration
0.5 ms) with an interpulse pause of 0.5 ms in combination with a bal-
anced gradient scheme. PCASL images were obtained in a dynamic
mode of 2 × 30 volumes (labeled and control) with an echo time of
14 ms, repetition time (TR) of 4200 ms, 23 axial slices, ﬁeld of view
(FOV) of 240 mm with an 80 × 80 matrix and an isotropic voxel size
of 3 × 3 × 6 mm.All 30 labeled and control volumes were ﬁrst motion-corrected in
SPM8 (Functional Imaging Laboratory, running in Matlab 7.10.0
(R2010a, Mathworks)). Volumes were smoothed with an 8 mm full-
width-at-half-maximum isotropic Gaussian kernel (FWHM). Next, vol-
umes were coregistered to the subject's own T1weighted images. Anal-
ogous to Van Dijk et al. (2010) labeled and control images were ﬁltered
against a time-course extracted froma ROI inwhitematter and cerebro-
spinal ﬂuid (CSF) drawn on a T1 image. Removal of signal from CSF and
white matter is motivated by the fact that these regions contain a rela-
tively high proportion of physiological noise (e.g. cardiac and respirato-
ry cycles). Thereafter, labeled perfusion-weighted images were
subtracted from control images, creating one mean PCASL image per
subject. These steps were performed using Matlab scripts developed
in-house.
FDG-PET imaging was performed in a 3D mode using a Siemens
Biograph mCT-64 PET scanner. Image acquisition was performed in a
resting state with the subject's eyes closed in a dimly lighted room
with minimal auditory stimulation. A 6-minute static frame was ac-
quired starting 30min after the injection of 200MBq FDG in 4ml saline.
The FDG-PET images were iteratively reconstructed using the OSEM
algorithmwith 3 iterations and 24 subsets on amatrix of 400 × 400 and
smoothedwith 5mmFWHM.No zoomwas applied, resulting in images
with an isotropic voxel-size of 2mmwith a speciﬁed resolution of 5mm
in the center of the ﬁeld of view. Scatter and attenuation corrections
were applied based on the acquired low dose CT.
A study-speciﬁc template of all mean PCASL images was spatially
normalized to a standard brain PET template (Montreal Neurological In-
stitute;MNI, supplied in SPM8) and then used to spatially normalize the
individual mean PCASL images. An example of the mean PCASL images
of seventeen healthy controls is shown in Fig. 1c. FDG-PET images were
directly spatially normalized to a PET template and then both were
smoothed with 10 mm FWHM.
2.3. Statistical analysis
SSM/PCAwas applied using software written in-house, based on the
methods of Spetsieris and Eidelberg (2011). The correctness of the in-
housewritten script was veriﬁed in an earlier validation study of the al-
ready identiﬁed PD,MSA and PSPmetabolic brain patterns (Teune et al.,
2010; Spetsieris and Eidelberg 2011). We performed both the analysis
with the Eidelberg software and our own software, which provided
identical results. A 35% threshold of the whole-brain intensity maxi-
mum was applied to remove out-of-brain voxels which results in a
mask of mainly gray matter, followed by a log transformation
(Spetsieris and Eidelberg 2011). This gray matter mask was applied to
the PCASL images without subsequent log transformation. After remov-
ing between-subject and between-region averages, a principal compo-
nent analysis (PCA) was applied. The components explaining the
largest amount of variance were selected. Together these components
accounted for at least 50% of the variance. A disease-related metabolic
covariance pattern was determined by a linear combination of the se-
lected principal components with the lowest AIC (Akaike information
criterion) value in a stepwise regression procedure. Thereafter, a
leave-one-out cross validation procedure was performed, providing an
average estimate of the disease-related metabolic brain patterns and
the error of this average per voxel. By dividing the average estimate
by its Standard Error of theMean, a T-scorewas obtained. Themetabolic
PD-related pattern (PDRP-mCT17HC19PD) was thresholded at T = 3.7
(corresponding to p = 0.001) assuming normality of data. The perfu-
sion brain pattern (PDRP-PCASL17HC14PD) was thresholded at T = 2.5
(corresponding to p = 0.02) and overlaid onto a T1 MR template
using MRIcron. For comparison purposes using the same HC and PD
subjects, a second metabolic brain pattern (PDRP-mCT17HC14PD) was
identiﬁed using the same threshold as for the perfusion pattern. Fur-
thermore, for PDRP-mCT17HC19PD, a leave-one-out cross validation was
performed. For each subject left out, its subject score was calculated
Fig. 1. A) (T)Map of the Parkinson's disease (PD)-relatedmetabolic brain patterns byusing 17 healthy controls (HC) and 19PD (PD) patients (PDRPmCT17HC19PD). Themapwas overlaid on
a T1MR template. Relativemetabolic decreases (blue) and increases (red) compared to the control group are thresholded at T=3.7–6.7 (p= 0.001). Seven transversal slices through the
brain are shown.B) (T) Maps of the PD-related metabolic and perfusion covariance brain patterns (PDRP-mCT17HC14PD and PDRP-PCASL17HC14PD) calculated by using the same HC and PD
subjects and overlaid on a T1MR template. Relativemetabolic and perfusion decreases (blue) and increases (red) compared to the control group are thresholded at T=2.5–5.0 (p= 0.02).
Seven transversal slices through the brain are shown.C) Example of themean PCASL images of all healthy controls. Seven transversal slices through the brain are shown. Yellow/red=high
perfusion, black/blue = low perfusion.
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scores were transformed into z-scores with respect to the healthy con-
trol population (z-score with a mean of zero and a standard deviation
of one) and displayed in a scatter plot. Receiver-operating-characteristic
(ROC) curves were determined for the probability values of PD. Opti-
mum cut-off probability values for classifying individual patients were
calculated by identifying an inﬂection point on the ROC curve that
corresponded to the best combination of sensitivity and speciﬁcity. Pa-
tients were classiﬁed as correctly diagnosed if their probability value
was higher than the cut-off value. Thereafter, we calculated sensitivity,
speciﬁcity, and positive and negative predictive values (PPV and NPV
respectively).
To compare the present PDRP-mCT17HC19PD using a high resolution
mCT camera with our previously published PD-related metabolic brain
pattern using an HR+ camera (PDRP-HR18HC20PD) (Teune et al., 2010)
z-scores were calculated for the HC and PD subjects scanned on the
mCT camera by using the PDRP-HR18HC20PD as a reference and vice
versa.
Moreover, subject scores of the PCASL images were calculated and
transformed into z-scores with respect to the PCASL healthy control
population using the PDRP-mCT17HC19PD as a reference.
3. Results
Spatial covariance analysis was performed on FDG-PET scans and
PCASL scans from PD patients. The model with the lowest AIC valueand hereafter considered as disease-related was determined by a linear
combination of principal components (PCs) 1, and 2 with variance
accounted for (VAF) of 27.1% (16.7 and 10.4% respectively) for PDRP-
mCT17HC19PD; PCs 1, 2, 4, and 5 (37.7% VAF (18.4, 8.9, 5.6 and 4.8% re-
spectively)) for PDRP-mCT17HC14PD and PCs 3 and 5 (16.1% VAF (9.9
and 6.1% respectively)) for PDRP-PCASL17HC14PD. A leave-one-out cross
validationwas subsequently performed resulting in disease-related pat-
terns (Fig. 1a,b). The PD-related metabolic covariance pattern (PDRP-
mCT17HC19PD) was characterized by relatively decreased cortical meta-
bolic activity in the temporal, posterior parietal, inferior parietal, lateral
occipital, and prefrontal association cortices and SMA. Relative increases
were seen in the cerebellum and pons, thalamus and pallidum, sensori-
motor cortex, limbic association cortex, paracentral lobule and left SMA
(Fig. 1a).
The PD-related perfusion covariance pattern (PDRP-PCASL17HC14PD)
was characterized by relatively decreased cortical perfusion activity bi-
laterally in the temporal, insular, posterior parietal, inferior parietal, lat-
eral occipital and prefrontal association cortices. Relative increaseswere
seen in the cerebellum and pons, right thalamus and pallidum, sensori-
motor cortex, paracentral lobule and supplementary motor area (SMA)
(Fig. 1b). In Fig. 1b the PD-related metabolic brain pattern was shown
using the same group as was used to determine the perfusion related
pattern (PDRP-mCT17HC14PD). The same regions were visible as in the
PDRPPDRP-mCT17HC19PD, although at a lower statistical threshold.
The corresponding z-scores showed an overlap between the
patients and healthy controls using PDRP-mCT17HC19PD. A cut-off value
243L.K. Teune et al. / NeuroImage: Clinical 5 (2014) 240–244of z=0.31 resulted in a sensitivity of 94.7%, positive predictive value of
75%, speciﬁcity of 64.7% and negative predictive value of 91.7% for cor-
rect PD classiﬁcation of an individual patient (Fig. 2a).
The PDRP-mCT17HC19PD z-scores did not correlate with the UPDRS
motor scores of PD patients (Spearman's rho = 0.294 and p= 0.222).
The present PD-related metabolic brain pattern using a high-
resolution mCT (PDRP-mCT17HC19PD) showed high reproducibility with
our previously published PD-related metabolic brain pattern using an
HR+ camera (PDRP-HR18HC20PD) (Fig. 2b). We computed the z-scores
of the FDG and PCASL images of 17 healthy controls and 14 PD patients
on the PDRP-mCT17HC19PD (Fig. 2c) and performed a correlation analysis.
The Pearson correlation coefﬁcient was 0.5 (p= 0.004).
4. Discussion
In this study we identiﬁed PD-related perfusion and glucose meta-
bolic brain patternsmeasured in the same patients. The PD-relatedmet-
abolic covariance brain pattern is in high accordance with previously
described disease-related metabolic brain patterns in different cohorts
in PD patients using standard clinical FDG-PET imaging (Ma et al.,
2007; Teune et al., 2013). The present PDRP-mCT17HC19PD did notFig. 2. A) Scatter plot and receiver-operating-characteristic (ROC) curve for the Parkinson's dise
patients (PDRP-mCT17HC19PD). On the y-axis of the scatter plot the leave-one-out z-scores are dis
point on the ROC curve (z-score); y-axis ROC curve = sensitivity, x-axis ROC curve = 1− spe
displaying z-scores for healthy controls and Parkinson's disease patients scanned on the high r
viously publishedmetabolic brain pattern on the HR+ camera (Teune et al., 2013) (PDRP-HR18H
PD subjects scanned on the HR+ camera (18HC-HR and 20PD-HR) by using PDRP-mCT17HC19PD
ease patients and their FDG and PCASL scans (17HC-FDG, 17HC-PCASL, 14PD-FDG and 14PD-PCA
reference.correlate with UPDRS motor scores. This is probably related to the rela-
tively short disease duration of the PD patients in comparison with pre-
vious reports with more advanced stage PD patients (Ma et al., 2010;
Tang et al., 2010b).
We obtained a disease-speciﬁc perfusion brain pattern using PCASL-
MR imaging. Our disease-related pattern is comparable to the PD-
related perfusion brain pattern described by Melzer et al. characterized
by decreased perfusion in the posterior parieto-occipital cortex, and
middle frontal gyri and preserved perfusion in the globus pallidus, puta-
men, anterior cingulate and post/precentral gyri (Melzer et al., 2011).
The most characteristic difference between our perfusion brain pattern
and previous reports is the decrease of cerebral perfusion in the insular
cortex on both sides in our data. However, Helmich et al. have shown
that PD patients had decreased connectivity between the posterior pu-
tamen and various cortical regions contributing to the corticostriatal
loop, including the insula using resting-state functional MRI data
(Helmich et al., 2010). Performing PCASL and FDG-PET imaging in the
same patients enabled a comparison between both patterns. z-Scores
of PCASL datasets onto the metabolic pattern correlated positively
(0.5) with the z-scores of FDG datasets onto the metabolic pattern.
This value indicates that there is an overlap, however, not complete.ase (PD)-relatedmetabolic brain pattern by using 17 healthy controls (HC) and 19 PD (PD)
played and on the x-axis the healthy control group and the PDpatient group. *= Inﬂection
ciﬁcity; PPV = positive predictive value; NPV = negative predictive value.B) Scatter plot
esolution mCT camera (17HC-mCT and 19PD-mCT (ﬁrst two columns)) by using the pre-
C20PD) as a reference. In the third and fourth columns z-scores are displayed for theHC and
as a reference.C) Scatter plot displaying z-scores for healthy controls and Parkinson's dis-
SL respectively) by using the PD-relatedmetabolic brain pattern (PDRP-mCT17HC19PD) as a
244 L.K. Teune et al. / NeuroImage: Clinical 5 (2014) 240–244As discussed above, there was a larger perfusion decrease in the PD-
related pattern in cortical regions including the insula than in the met-
abolic brain pattern.
Another difference is the less pronounced increased perfusion in the
basal ganglia in the perfusion-related pattern compared to themetabol-
ic brain pattern. This is probably related to a lower signal-to-noise ratio.
It is known that MRI head coils with multiple receive channels result in
better signal to noise ratio in the cortex than in deeper brain structures.
Our data shows that PCASL is a promising technique, which could be
developed further as an additional measurement to improve image-
based diagnosis of parkinsonian syndromes. Our results need to be rep-
licated in larger samples, particularly in prospective validation samples
and especially in PCASL data.
5. Conclusion
We identiﬁed PD-related perfusion and metabolic brain patterns
using PCASL and FDG-PET in the same patients which were comparable
with results of existing research. In this respect, PCASL appears to be a
promising addition in the early diagnosis of individual parkinsonian
patients.
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